The Clinical Trial of Pandemic Influenza Vaccine (Whole-Virion Inactivated, Adjuvanted) on Healthy Adults by Randomized and Double-Blind Design: a Phase II Study
Latest Information Update: 26 Apr 2013
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype; Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sinovac Biotech
- 15 Apr 2009 Results published in Clinical Infectious Diseases.
- 16 May 2008 Production license from the China State Food and Drug Administration (SFDA) for exclusive supply of Panflu to the national stockpiling program.
- 24 Dec 2007 Status changed from recruiting to completed; this trial has been reported as completed in a Sinovac media release.